We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
|Bid||48.76 x 1100|
|Ask||48.77 x 1000|
|Day's Range||48.57 - 48.98|
|52 Week Range||48.42 - 81.44|
|Beta (5Y Monthly)||0.37|
|PE Ratio (TTM)||12.40|
|Earnings Date||Feb 02, 2024|
|Forward Dividend & Yield||2.28 (4.66%)|
|Ex-Dividend Date||Oct 05, 2023|
|1y Target Est||63.23|
Subscribe to Yahoo Finance Plus to view Fair Value for BMY
Bayer (BAYRY) shares closed 17% lower on Monday after the company halted a trial for a blood-thinning drug due to "lack of efficacy." The news sent shares of Bristol Myers Squibb (BMY) lower because it's developing a similar drug. Also impacting Bayer shares is the news that the company was ordered to pay $1.56 billion in a lawsuit involving its Roundup weedkiller. Yahoo Finance Live breaks down the stock action. Click here to watch the full interview on the Yahoo Finance YouTube page or you can watch this full episode of Yahoo Finance Live here.
Wall Street's three major stock averages closed higher on Monday with Nasdaq's 1% rally leading the charge as heavyweight Microsoft hit a record high after it hired prominent artificial intelligence executives. The Nasdaq boasted its highest closing level since July 31 while the S&P 500 registered its highest close since Aug. 1.
Shares fell sharply after the company stopped a late-stage study for a cardiovascular drug because of lack of efficacy and was ordered to pay around $1.6 billion in a lawsuit relating to its Roundup weedkiller.
Wall Street's three major U.S. stock averages advanced on Monday with Nasdaq leading gains as heavyweight Microsoft rallied after it hired prominent artificial intelligence executives, and lower Treasury yields also provided some support. The S&P 500 information technology sub-index, up 1.6%, was the top gainer among the S&P 500's 11 major sectors, getting its biggest boost from Microsoft's shares which touched a record high and were last up 2%.
German drugmaker Bayer scrapped a late-stage trial of an experimental blood thinner that could have major implications for Bristol Myers.
U.S. equities began the holiday-shortened trading week higher at midday on Monday, Nov. 20, 2023 after optimism about slowing inflation buoyed markets last week.
Bristol-Myers Squibb and 2seventy bio shares dropped after the FDA said it would not make a decision on expanded use of the companies' cancer drug next month.
The week is off to an ugly start for some pharmaceutical investors. Bayer said it is [halting a trial for asundexian](https://www.wsj.com/health/pharma/bayer-shares-tumble-after-clinical-trial-failure-roundup-case-loss-507c1ae0), an experimental cardiovascular drug, due to a lack of efficacy in treating patients with atrial fibrillation, a condition that causes an irregular heartbeat.
Bristol Myers Squibb (NYSE: BMY), or BMS for short, is starting the week off on a sour note. Specifically, the drugmaker's shares fell by as much as 4% in early action Monday. BMS' stock has rebounded modestly as today's session has progressed, but the pharmaceutical company's shares were still in the red by 2.16% as of 10:28 a.m. ET Monday.
↗️ [**Microsoft (MSFT)**](https://www.wsj.com/market-data/quotes/MSFT): The software giant [said](https://www.wsj.com/tech/ai/openai-leadership-hangs-in-balance-as-sam-altmans-counte-rebellion-gains-steam-47276fa8) it hired Sam Altman, days after he was ousted as chief executive of OpenAI, to lead a new artificial-intelligence research team.
|Symbol||Last Price||Change||% Change|
Merck & Co., Inc.
Eli Lilly and Company
|Symbol||Last Price||Change||% Change|
Merck & Co., Inc.
Johnson & Johnson
|Downgrade||Cantor Fitzgerald: Overweight to Neutral||11/15/2023|
|Initiated||Deutsche Bank: to Hold||11/9/2023|
|Downgrade||Daiwa Capital: Outperform to Neutral||11/2/2023|
|Maintains||Goldman Sachs: Buy to Buy||10/30/2023|
|Maintains||Morgan Stanley: Underweight to Underweight||10/27/2023|
|Maintains||Barclays: Equal-Weight to Equal-Weight||10/27/2023|
Industry: Drug Manufacturers - General
Full Time Employees: 34,300
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.